Cynvec was founded in 2004 to develop and commercialize innovative safe and effective cancer treatments based on intellectual property exclusively licensed from New York University (NYU). Our first product candidate, CYN-101, is a vaccine designed to target ovarian cancer. It utilizes the anti-cancer properties of a bio-engineered form of the naturally-occurring Sindbis virus that expresses a tumor associated antigen derived from the pioneering work of Dr. Daniel Meruelo, a NYU professor who is a leading authority on the Sindbis virus.
View Top Employees from Cynvec LLC| Website | http://www.cynvec.com |
| Revenue | $6 million |
| Employees | View employees |
| Founded | 2004 |
| Address | 120 W 45th St Ste 3600, New York, New York 10036, US |
| Phone | (340) 998-2258 |
| Industry | Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Medical |
| Competitors | Adze Biotechnology Inc, PxRadia, Inc., Veana Therapeutics Inc. |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 54 Companies, NAICS Code 54171 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular Cynvec LLC employee's phone or email?
Cynvec LLC Questions
The Cynvec LLC annual revenue was $6 million in 2023.
Cynvec LLC is based in New York, New York.
The NAICS codes for Cynvec LLC are [54, 54171, 541714, 541, 5417].
The SIC codes for Cynvec LLC are [87, 873].
